Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
MGB Biopharma
MGB Biopharma
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
You need to be a subscriber to read this article.
Click here
to find out more.
Research & Development
Can new discoveries prevent an antibiotic Armageddon?
Governments are waking up to the catastrophe of drug resistance and healthcare without antibiotics. But is extra funding the answer or could the pharma industry be doing more?
Research & Development
MGB Biopharma secures funding of £4m to take new antibacterial into clinical development
MGB-BP-3 has a new mode of action and is a novel class of anti-infective, the company says
Manufacturing
MGB Biopharma and Almac collaborate on contract manufacturing project
Almac to manufacture antibacterial compound MGB-BP3 for Glasgow firm
Research & Development
MGB Biopharma develops more effective antibiotic for C.Diff
Clinical trials are scheduled for 2012
Subscribe now